Treatment News : Many People With HIV Could Switch to Newer, Safer Regimens

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » July 2014

Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

July 15, 2014

Many People With HIV Could Switch to Newer, Safer Regimens

A majority of people taking antiretrovirals (ARVs) to treat HIV could switch to newer regimens with improved side effect profiles, according to an analysis of Australians living with the virus, aidsmap reports. Publishing their findings in PLOS ONE, researchers analyzed the treatment history and drug resistance information of 120 people taking two or more of four commonly used, relatively older ARVs that come with notable safety and tolerability concerns.

The researchers dubbed the four ARVs in question the “RATE” drugs after their generic names: Norvir (ritonavir), which has drug interaction problems; Ziagen (abacavir), which can cause an allergic reaction, is less potent when viral loads are higher and may elevate the risk of cardiovascular disease; Viread (tenofovir), which may reduce bone density and cause kidney dysfunction; and Sustiva (efavirenz), which is linked to neuropsychiatric disturbances and raised lipid levels.

By comparison, the following drugs have been approved more recently and boast improved tolerability: Edurant (rilpivirine), Intelence (etravirine), Reyataz (atazanavir), Isentress (raltegravir) and Selzentry (maraviroc). And then there is the older Epivir (lamivudine), which also has a better side effect profile.

Genetic testing of the virus, necessary to determine if Selzentry would be a viable option, was not available for 54 percent of the participants and was not successful for 8 percent of them.

If all the participants were indeed susceptible to Selzentry, then the researchers estimated that 98 percent of them could feasibly switch to at least one ARV regimen with two safer active drugs. Eighty-nine percent could switch to a regimen with three of the safer options. These percentages dropped to a respective 94 percent and 87 percent when factoring in the unknown Selzentry susceptibility.

After conducting an analysis of the Australian HIV Observational Database (AHOD), the investigators found that 57 percent of Australians were on ARV regimens including two or more RATE drugs and could potentially switch to newer therapies.

To read the aidsmap story, click here.

To read the study, click here.

Search: HIV, aidsmap, PLOS ONE, safer regimens, Norvir, ritonavir, Ziagen, abacavir, Viread, tenofovir, Sustiva, efavirenz, Edurant, rilpivirine, Intelence, etravirine, Reyataz, atazanavir, Isentress, raltegravir, Selzentry, maraviroc, Epivir, lamivudine.


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)

 
[Go to top]


Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    dversescott
    Baltimore
    Maryland


    usuallyhappy
    Palm Springs
    California


    OahuAJ
    Glendora
    California


    clintonjrsyr
    syracuse
    New York
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Is HIV/AIDS adequately portrayed in pop culture?
Yes
No

Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.